Combination Therapy of Aspirin and Apyrase for Stroke

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43NS071655-01
Agency Tracking Number: NS071655
Amount: $287,622.00
Phase: Phase I
Program: SBIR
Awards Year: 2010
Solitcitation Year: 2010
Solitcitation Topic Code: NINDS
Solitcitation Number: PHS2010-2
Small Business Information
APT THERAPEUTICS, INC., 4041 Forest Park Avenue, SAINT LOUIS, MO, 63108
Duns: 192266141
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (312) 339-8455
Business Contact
Phone: (312) 339-8455
Research Institution
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. We will validate hypothesis that in thromboembolic model of stroke in rats, combination treatment of ASA plus apyrase at acute stage provides more effective protection than ASA or apyrase alone in short term as well as long-term experiments without increasing intracerebral hemorrhage. PUBLIC HEALTH RELEVANCE: We will utilize clinically relevant embolic stroke models in rats to assess neuroprotective effect of aspirin and apyrase treatment.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government